

Edgar Filing: TARO PHARMACEUTICAL INDUSTRIES LTD - Form 6-K

TARO PHARMACEUTICAL INDUSTRIES LTD
Form 6-K
May 07, 2010

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE
SECURITIES EXCHANGE ACT OF 1934

For the month of May, 2010

Commission File Number 000-22286

Taro Pharmaceutical Industries Ltd.
(Translation of registrant's name into English)

14 Hakitor Street, Haifa Bay 26110, Israel
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports
under cover of Form 20-F or Form 40-F.

Form 20-F Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as
permitted by Regulation S-T Rule 101(b)(1): _____

Indicate by check mark if the registrant is submitting the Form 6-K in paper as
permitted by Regulation S-T Rule 101(b)(7): _____

Indicate by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes No

If "Yes" is marked, indicate below the file number assigned to the registrant in
connection with Rule 12g3-2(b): 82-_____.

On April 30, 2010 the Company notified its shareholders that an Extraordinary
General Meeting of the Shareholders will be held on May 21, 2010 for the purpose
of considering the termination of the appointment of Kost Forer Gabbay and
Kasierer, a member of Ernst & Young Global ("EY") as the Company's independent
auditors and appointing Ziv Haft, Certified Public Accountants (Israel), a BDO
member firm, in their place.

On May 6, 2010 the Company received a letter from EY which read as follows:

"This is to confirm that the client-auditor relationship between Taro
Pharmaceutical Industries ltd. (Commission File Number 000-22286) and Kost
Forer Gabbay and Kasierer, a member of Ernst & Young Global has ceased."

The Company plans to proceed with the Extraordinary General Meeting on May 21st,
as previously announced.

SIGNATURES

Edgar Filing: TARO PHARMACEUTICAL INDUSTRIES LTD - Form 6-K

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: May 7, 2010

TARO PHARMACEUTICAL INDUSTRIES LTD.

By: /s/ Ron Kolker

Name: Ron Kolker

Title: Senior Vice President,
Chief Financial Officer